(Q38174770)

30 August 2017

title

Epidermal growth factor receptor mutations in lung adenocarcinoma (English)

1 reference

30 August 2017

1 reference

Markus D Siegelin

1

1 reference

30 August 2017

Alain C Borczuk

series ordinal

2

1 reference

30 August 2017

publication date

30 December 2013

1 reference

30 August 2017

published in

Laboratory Investigation

1 reference

30 August 2017

volume

94

1 reference

30 August 2017

issue

2

1 reference

30 August 2017

page(s)

129-137

1 reference

https://scigraph.springernature.com/pub.10.1038/labinvest.2013.147

30 August 2017

exact match

0 references

cites work

EGFR mutations and lung cancer

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

EGF receptor in neoplasia and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Signal transduction by receptors with tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Receptors for epidermal growth factor and other polypeptide mitogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Regulation of MAP kinase activity by peptide receptor signalling pathway: paradigms of multiplicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Epidermal growth factor receptor: mechanisms of activation and signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Molecular dissection of AKT activation in lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

STAT3 expression in activating EGFR-driven adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

New driver mutations in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

In cancer drug resistance, germline matters too.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

ROS1 rearrangements define a unique molecular class of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Disproportionate representation ofKRAS gene mutation in atypical adenomatous hyperplasia, but even distribution ofEGFR gene mutation from preinvasive to invasive adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLABINVEST.2013.147

Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).

21 January 2018

1 reference

12 December 2020

The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase

1 reference

12 December 2020

EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients

1 reference

12 December 2020

Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L

1 reference

12 December 2020

Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations

1 reference

12 December 2020

Overexpression of circulating c-met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer.

1 reference

12 December 2020

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

1 reference

12 December 2020

10.1038/LABINVEST.2013.147

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1001165371

0 references

1 reference